OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

INTRODUCTION: A prespecified pooled analysis of two placebo-controlled, phase 3 trials evaluated whether the number of prior anticholinergics used or reason for their discontinuation affected the treatment response to onabotulinumtoxinA 100U in overactive bladder (OAB) patients with urinary incontin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sievert, K-D, Chapple, C, Herschorn, S, Joshi, M, Zhou, J, Nardo, C, Nitti, V W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282287/
https://www.ncbi.nlm.nih.gov/pubmed/24754838
http://dx.doi.org/10.1111/ijcp.12443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282287/
https://www.ncbi.nlm.nih.gov/pubmed/24754838
http://dx.doi.org/10.1111/ijcp.12443

Ejemplares similares